Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study.
pain
safety
sickle cell disease
ticagrelor
vaso-occlusion crisis
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
18
11
2018
medline:
19
9
2019
entrez:
17
11
2018
Statut:
ppublish
Résumé
Ticagrelor is an antiplatelet agent for adults with coronary artery disease. The inhibition of platelet activation may decrease the frequency of vaso-occlusion crisis (VOC) in sickle cell disease (SCD). The HESTIA2 study (NCT02482298) randomised 87 adults with SCD (aged 18-30 years) 1:1:1 to twice-daily ticagrelor 10, 45 mg or placebo for 12 weeks. Numerical decreases from baseline in mean proportion of days with patient-reported pain (primary endpoint) were seen in all three groups, as well as in pain intensity and analgesic use, with no significant differences between placebo and ticagrelor treatment groups. Plasma ticagrelor concentrations and platelet inhibition increased with dose. Adverse events were distributed evenly across groups and two non-major bleeding events occurred per group. Ticagrelor was well tolerated with a low bleeding risk, but no effect on diary-reported pain was detected. Potential effects on frequency of VOCs will need to be evaluated in a larger and longer study.
Identifiants
pubmed: 30443999
doi: 10.1111/bjh.15646
pmc: PMC6587797
doi:
Substances chimiques
Analgesics
0
Platelet Aggregation Inhibitors
0
Ticagrelor
GLH0314RVC
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
269-278Informations de copyright
© 2018 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
JAMA. 2014 Sep 10;312(10):1033-48
pubmed: 25203083
Chest. 2016 Apr;149(4):1082-93
pubmed: 26836899
Lancet. 2017 Jul 15;390(10091):311-323
pubmed: 28159390
Clin Pharmacokinet. 2015 Nov;54(11):1125-38
pubmed: 26063049
PLoS One. 2013 Nov 05;8(11):e79923
pubmed: 24224021
Thromb Haemost. 2017 Feb 28;117(3):580-588
pubmed: 27929203
Pediatr Blood Cancer. 2012 Apr;58(4):584-90
pubmed: 21584938
Circulation. 2009 Dec 22;120(25):2577-85
pubmed: 19923168
J Pain. 2016 Nov;17(11):1227-1236
pubmed: 27555427
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
J Thromb Haemost. 2011 Sep;9(9):1856-8
pubmed: 21884565
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2299-306
pubmed: 20688583
N Engl J Med. 2016 Feb 18;374(7):625-35
pubmed: 26644172
Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1626-31
pubmed: 16601237
Agents Actions Suppl. 1984;15:199-212
pubmed: 6385647
Br J Clin Pharmacol. 2010 Jul;70(1):65-77
pubmed: 20642549
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
J Thromb Haemost. 2009 Sep;7(9):1556-65
pubmed: 19552634
Am J Hematol. 2011 Feb;86(2):203-5
pubmed: 21264908
J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):209-19
pubmed: 24414167
Blood. 2001 Sep 15;98(6):1955-62
pubmed: 11535535
J Hematol Oncol. 2013 Feb 17;6:17
pubmed: 23414938
PLoS One. 2012;7(1):e29786
pubmed: 22253781
N Engl J Med. 2017 Feb 2;376(5):429-439
pubmed: 27959701
Ann Intern Med. 2008 Jan 15;148(2):94-101
pubmed: 18195334